Prediction Case File
YouTubeEvaluation Complete

Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]

1 extracted signal · 1 resolved · 0 still active

StockInvest.us profile imageStockInvest.usIndependent analyst profile
Source published
20 Nov 2025, 04:52 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]
Source overview

AI-generated source summary

Nuvation Bio Inc. (NUVB) is currently ranked as a Hold/Accumulate, exhibiting a score of 0, indicating significant volatility. The stock achieved a 93.24% gain over the past 23 days since initial recommendation, with an average daily gain of 4.05%. Technical analysis shows a break through a wide and strong short-term rising trend, suggesting continued upward momentum. According to fan theory, a resistance point and potential peak is projected at $7.51. The three-month outlook anticipates a 75.19% change, with returns ranging from 12.53% to 48.26%. The 12-month analysis projects a 57.48% change, with prices potentially fluctuating between $3.88 and $7.52. On the last trading day, NUVB closed at $7.15, marking a nearly 49% increase from its opening price of $4.80, with a notable trading volume of 59 million shares ($420.02 million). The 52-week high reached $7.35, while the low was $1.54. The stock is 2.72% below its 52-week high. News surrounding the commercialization of its lung cancer drug, Ibtrozi, and positive patient enrollment reports are supportive. However, a modest institutional stake was disclosed, and insider trading activity includes a chief scientist selling 100,000 shares, balancing optimism with caution. Nuvation's pipeline advancement in high-grade IDH1-mutant glioma presents a potential long-term value driver. Expect near-term volatility driven by market metrics and options activity. The stock exhibits a negative P/E ratio of -11.26, indicating negative earnings. Support levels are identified at $5.15 and $4.48, with a critical support from accumulated volume at $5.37. Daily average volatility is 17.46%, classifying the stock risk as medium. Moving Averages show mixed signals in the short term (MACD: Sell, Short MA: Sell, Long MA: Sell), but the long-term Short MA is a Buy, and the cross between MA35/MA100 is a Buy. A buy signal was issued from a pivot bottom 39 days ago. The suggested stop-loss is $6.90 (-3.56%). Our analysis concludes that NUVB is currently overvalued and should be considered a hold candidate due to minor technical weaknesses, with an anticipated open lower by $0.670 at $6.48 on Thursday, November 20th.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

StockInvest.us

Platform-wide history, separate from this source evaluation.

Reliability
53.4
Tracked signals
1779
Historical success
42.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail